Nanocarriers Used in Drug Delivery to Enhance Immune System in Cancer Therapy

Lôbo, Giovanna C. N. B.; Paiva, Karen L. R.; Silva, Ana Luísa G.; Simões, Marina M.; Radicchi, M; Báo, Sônia Nair

doi:10.3390/pharmaceutics13081167

Cited by 34 publications

(14 citation statements)

References 174 publications

(235 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, a variety of efficient novel delivery systems have been developed, e.g. virus-based delivery systems, cationic lipid delivery systems, polymer delivery systems and antibodies ( 183 ). These delivery systems not only enhance the delivery efficiency of ncRNAs but also improve their biological stability and pharmacokinetic distribution.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, excessive cationic components readily cause decomposition of the carrier particles at the glomerular basement membrane, resulting in renal clearance of ncRNAs ( 175 ). Although scientific researchers have made great efforts to design a variety of promising noncationic nucleic acid carriers (octameric ribonucleoprotein, exosomes, spherical nucleic acids and siRNA conjugates) to load ncRNAs ( 183 , 184 ), viral vectors and cationic nanoparticles are still the most commonly used delivery methods in ncRNA therapy. In other words, the toxicity and immunogenicity of nucleic acid carrier systems cannot be overcome at present.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review)

et al. 2022

View full text Add to dashboard Cite

As the most common primary tumour of the central nervous system, gliomas have a high recurrence rate after surgical resection and are resistant to chemotherapy, particularly high-grade gliomas dominated by glioblastoma multiforme (GBM). The prognosis of GBM remains poor despite improvements in treatment modalities, posing a serious threat to human health. At present, although drugs such as temozolomide, cisplatin and bevacizumab, are effective in improving the overall survival of patients with GBM, most patients eventually develop drug resistance, leading to poor clinical prognosis. The development of multidrug resistance has therefore become a major obstacle to improving the effectiveness of chemotherapy for GBM. The ability to fully understand the underlying mechanisms of chemotherapy resistance and to develop novel therapeutic targets to overcome resistance is critical to improving the prognosis of patients with GBM. Of note, growing evidence indicates that a large number of abnormally expressed noncoding RNAs (ncRNAs) have a central role in glioma chemoresistance and may target various mechanisms to modulate chemosensitivity. In the present review, the roles and molecular mechanisms of ncRNAs in glioma drug resistance were systematically summarized, the potential of ncRNAs as drug resistance markers and novel therapeutic targets of glioma were discussed and prospects for glioma treatment were outlined. ncRNAs are a research direction for tumor drug resistance mechanisms and targeted therapies, which not only provides novel perspectives for reversing glioma drug resistance but may also promote the development of precision medicine for clinical diagnosis and treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review)

et al. 2022

View full text Add to dashboard Cite

show abstract

“…For example, targeting cells with spatially constrained 2-in-1 nanomedicine delivery systems has been proved to enhance efficacy compared to single drug payload stochastic distribution. [70] Despite of promising drug delivery nanocarriers that modulate tumoral immune response, [71] these novel approaches still bear some limitations, such as premature drug release, delivery to off-target clearance organs, nanocarrier instability or systemic toxicity. [69] In this study we addressed the question of repolarizing tumor associated macrophages toward a more tumoricidal phenotype in safer manner by developing and testing the uptake of CSF1Ri-loaded PMs, evaluating their toxicity and comparing the effect of free versus PMs encapsulated CSF1Ri on M2-to M1like macrophage repolarization and survival of cocultured breast cancer cell in vitro model.…”

Section: Discussionmentioning

confidence: 99%

“…For example, targeting cells with spatially constrained 2‐in‐1 nanomedicine delivery systems has been proved to enhance efficacy compared to single drug payload stochastic distribution. [ 70 ] Despite of promising drug delivery nanocarriers that modulate tumoral immune response, [ 71 ] these novel approaches still bear some limitations, such as premature drug release, delivery to off‐target clearance organs, nanocarrier instability or systemic toxicity. [ 69 ]…”

Section: Discussionmentioning

confidence: 99%

Polymersomes‐Mediated Delivery of CSF1R Inhibitor to Tumor Associated Macrophages Promotes M2 to M1‐Like Macrophage Repolarization

Rodriguez‐Perdigon

Jimaja

Haen

et al. 2022

Macromolecular Bioscience

View full text Add to dashboard Cite

The crosstalk between cancer cells and tumor associated macrophages (TAMs) within the tumor environment modulates tumor progression at all stages of cancer disease. TAMs are predominantly M2-like polarized macrophages with tumor-promoting activities. Nonetheless, they can be repolarized to tumoricidal M1-like macrophages through macrophage colony stimulating factor 1 receptor inhibition (CSF1Ri). CSF1Ri is being explored as multifaced therapeutic approach to suppress TAMs tumorpromoting functions and reduce cancer cell aggressiveness and viability. However, treatment with CSF1Ri results in significant TAMs death, thereby extinguishing the possibility of generating tumoricidal M1-like macrophages. Immunotherapy has improved overall patient's survival in some cancer types, but also caused frequent off-target toxicity. Approaches to balance efficacy vs toxicity are needed. Herein, a CSF1Ri loaded polymersomes (PM) based delivery platform is developed to promote M2-like macrophage repolarization. When testing in vitro on primary human monocyte-derived macrophages (MDMs), CSF1Ri loaded PM are preferentially taken up by M2-like macrophages and enhance M2 to M1-like macrophage repolarization while minimizing cytotoxicity in comparison to the free drug. When testing in a MDMs-MDA-MB-231 breast cancer cell co-culture model, CSF1Ri loaded PM further retain their M2 to M1-like macrophages polarization capacity. This CSF1Ri loaded PMbased platform system represents a promising tool for macrophage-based immunotherapy approaches.Received: ((will be filled in by the editorial staff))Revised: ((will be filled in by the editorial staff))

show abstract

“…It is developed in the primary tumor in which the cancer cell escapes from the immune system and forms the secondary tumor at distant organs [ 3 , 4 , 5 ]. Recently, immune therapy held promise to suppress the metastatic cells via the cytotoxic T lymphocytes [ 6 , 7 , 8 ]. Despite the recent advance in immunotherapy, the invading clusters of metastases usually smaller than 100 mm 3 poorly performed vascularization and restricted physical contact of T lymphocytes, lowering immune responses [ 9 , 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Programmed Catalytic Therapy-Mediated ROS Generation and T-Cell Infiltration in Lung Metastasis by a Dual Metal-Organic Framework (MOF) Nanoagent

et al. 2022

View full text Add to dashboard Cite

Nano-catalytic agents actuating Fenton-like reaction in cancer cells cause intratumoral generation of reactive oxygen species (ROS), allowing the potential for immune therapy of tumor metastasis via the recognition of tumor-associated antigens. However, the self-defense mechanism of cancer cells, known as autophagy, and unsustained ROS generation often restricts efficiency, lowering the immune attack, especially in invading metastatic clusters. Here, a functional core-shell metal-organic framework nanocube (dual MOF) doubling as a catalytic agent and T cell infiltration inducer that programs ROS and inhibits autophagy is reported. The dual MOF integrated a Prussian blue (PB)-coated iron (Fe2+)-containing metal-organic framework (MOF, MIL88) as a programmed peroxide mimic in the cancer cells, facilitating the sustained ROS generation. With the assistance of Chloroquine (CQ), the inhibition of autophagy through lysosomal deacidification breaks off the self-defense mechanism and further improves the cytotoxicity. The purpose of this material design was to inhibit autophagy and ROS efficacy of the tumor, and eventually improve T cell recruitment for immune therapy of lung metastasis. The margination and internalization-mediated cancer cell uptake improve the accumulation of dual MOF of metastatic tumors in vivo. The effective catalytic dual MOF integrated dysfunctional autophagy at the metastasis elicits the ~3-fold recruitment of T lymphocytes. Such synergy of T cell recruitment and ROS generation transported by dual MOF during the metastases successfully suppresses more than 90% of tumor foci in the lung.

show abstract

Nanocarriers Used in Drug Delivery to Enhance Immune System in Cancer Therapy

Cited by 34 publications

References 174 publications

NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review)

NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review)

Polymersomes‐Mediated Delivery of CSF1R Inhibitor to Tumor Associated Macrophages Promotes M2 to M1‐Like Macrophage Repolarization

Programmed Catalytic Therapy-Mediated ROS Generation and T-Cell Infiltration in Lung Metastasis by a Dual Metal-Organic Framework (MOF) Nanoagent

Contact Info

Product

Resources

About